Previous 10 | Next 10 |
2023-03-24 14:03:55 ET Summary Organon & Co. has seen mostly margin disappointments since the spinoff from Merck & Co., Inc. While the performance is not comforting, valuations are non-demanding. Leverage is high, but stabilization in the business, longer-term maturiti...
2023-03-16 08:34:23 ET Raymond James launched its coverage on Organon ( NYSE: OGN ) with an Outperform recommendation citing its potential in the biosimilar space with the upcoming launch of Hadlima, a copycat version of AbbVie's ( ABBV ) blockbuster arthritis therapy Humira...
2023-03-12 10:00:00 ET Biosimilar medication, generic versions of typically expensive biologic-based drugs, are set to save patients and the health care system $180B over the next five years as even more hit the market. New launches and an expected increase in uptake of biosimilars ...
Building on Organon’s Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Experience Unplanned Pregnancies Each Year Organon (NYSE: OGN), a global healthcare c...
2023-03-06 23:01:05 ET Summary Kahn Brothers’ 13F portfolio value increased from ~$642M to ~$760M this quarter. Most of the stakes saw minor adjustments during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~49% o...
Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace Canada NewsWire The WiG evaluation, which comprises over 75 quantitative and qualitative criteria, showcases Organon Canada's ...
Sydney, Australia (ABN Newswire) - Moneghetti Minerals Limited (Moneghetti, the Company) today announced it has identified new high-priority drill targets at the Company's flagship Ecru Gold Project (Ecru) located in the well endowed Cortez District, Nevada USA. The Ecru Project is a Carlin-t...
Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health Canada NewsWire 170 employees across Canada will receive paid time off and join 10,000 Organon employees w...
Summary Merck has seen a significant valuation re-rating take place over the past years. This comes amidst the success of Keytruda, which creates some dependency risks as well. With no growth seen in 2023, amidst tough comparables from a pandemic-related contribution in 2022, I am a...
Shares of Organon (NYSE: OGN) fell 15% on Thursday. The pharmaceutical company, which focuses on women's health therapies, established medicines, and biosimilars, reported fourth-quarter and full-year numbers that came in below analysts' consensus expectations. The stock ended the session...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...